Maturing neutrophils of lower density associate with thrombocytopenia in Puumala orthohantavirus-caused hemorrhagic fever with renal syndrome.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2024
Historique:
received: 18 04 2024
accepted: 29 05 2024
medline: 16 7 2024
pubmed: 16 7 2024
entrez: 16 7 2024
Statut: epublish

Résumé

Puumala orthohantavirus-caused hemorrhagic fever with renal syndrome (PUUV-HFRS) is characterized by strong neutrophil activation. Neutrophils are the most abundant immune cell type in the circulation and are specially equipped to rapidly respond to infections. They are more heterogenous than previously appreciated, with specific neutrophil subsets recently implicated in inflammation and immunosuppression. Furthermore, neutrophils can be divided based on their density to either low-density granulocytes (LDGs) or "normal density" polymorphonuclear cell (PMN) fractions. In the current study we aimed to identify and characterize the different neutrophil subsets in the circulation of PUUV-HFRS patients. PMNs exhibited an activation of antiviral pathways, while circulating LDGs were increased in frequency following acute PUUV-HFRS. Furthermore, cell surface marker expression analysis revealed that PUUV-associated LDGs are primarily immature and most likely reflect an increased neutrophil production from the bone marrow. Interestingly, both the frequency of LDGs and the presence of a "left shift" in blood associated with the extent of thrombocytopenia, one of the hallmarks of severe HFRS, suggesting that maturing neutrophils could play a role in disease pathogenesis. These results imply that elevated circulating LDGs might be a general finding in acute viral infections. However, in contrast to the COVID-19 associated LDGs described previously, the secretome of PUUV LDGs did not show significant immunosuppressive ability, which suggests inherent biological differences in the LDG responses that can be dependent on the causative virus or differing infection kinetics.

Identifiants

pubmed: 39011044
doi: 10.3389/fimmu.2024.1419787
pmc: PMC11246883
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1419787

Informations de copyright

Copyright © 2024 Cabrera, Tietäväinen, Jokiranta, Mäkelä, Vaheri, Mustonen, Vapalahti, Kanerva and Strandin.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Luz E Cabrera (LE)

Viral Zoonosis Research Unit, Department of Virology, Medicum, University of Helsinki, Helsinki, Finland.

Johanna Tietäväinen (J)

Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Department of Internal Medicine, Tampere University Hospital, Tampere, Finland.

Suvi T Jokiranta (ST)

Department of Bacteriology and Immunology, University of Helsinki, Helsinki, Finland.
Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.

Satu Mäkelä (S)

Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Department of Internal Medicine, Tampere University Hospital, Tampere, Finland.

Antti Vaheri (A)

Viral Zoonosis Research Unit, Department of Virology, Medicum, University of Helsinki, Helsinki, Finland.

Jukka Mustonen (J)

Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Department of Internal Medicine, Tampere University Hospital, Tampere, Finland.

Olli Vapalahti (O)

Viral Zoonosis Research Unit, Department of Virology, Medicum, University of Helsinki, Helsinki, Finland.

Mari Kanerva (M)

Infectious Diseases, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Tomas Strandin (T)

Viral Zoonosis Research Unit, Department of Virology, Medicum, University of Helsinki, Helsinki, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH